Owen Osagie, MD
Psychiatry · Rosenberg, TXNPI 1164534426
Payments from drug & device makers
Across 462 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$995
- Alkermes, Inc.$920
- Johnson & Johnson$699
- plus $3K from 16 others
What the payments were for
- Food & beverage$9,03695%
- Education$5105%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 72 | $2,055 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,173 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,042 |
| Neurocrine Biosciences, Inc. | 51 | $995 |
| Alkermes, Inc. | 31 | $920 |
| Johnson & Johnson | 47 | $699 |
| AbbVie(2 entities) | 36 | $607 |
| Sunovion Pharmaceuticals Inc. | 22 | $406 |
| Ironshore Pharmaceuticals Inc. | 16 | $328 |
| Indivior Inc. | 19 | $308 |
| E.r. Squibb & Sons, L.L.C. | 17 | $268 |
| Supernus Pharmaceuticals, Inc. | 14 | $213 |
| Corium, LLC | 8 | $194 |
| Vanda Pharmaceuticals Inc. | 8 | $186 |
| Noven Therapeutics, LLC | 2 | $34 |
| Almatica Pharma LLC | 1 | $27 |
| Livanova USA, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,000
- LYBALVI$463
- CAPLYTA$251
- ARISTADA INITIO$250
- ABILIFY MAINTENA$242
- UZEDY$225
- Austedo XR$216
- VRAYLAR$206
- INVEGA SUSTENNA$128
- REXULTI$125
- ABILIFY ASIMTUFII$122
- LATUDA$121
- JORNAY PM$121
How this compares
$9,546 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $185,748 |
| Invega TrinzaPaliperidone Palmitate | 24 | $172,914 |
| Invega SustennaPaliperidone Palmitate | 35 | $88,602 |
| AustedoDeutetrabenazine | 13 | $88,516 |
| Abilify MaintenaAripiprazole | 20 | $49,605 |
| Aripiprazole | 49 | $6,911 |
| Divalproex Sodium ErDivalproex Sodium | 76 | $5,185 |
| Olanzapine | 123 | $2,673 |
| Risperidone | 190 | $1,765 |
| Benztropine Mesylate | 107 | $1,482 |
| Bupropion XlBupropion Hcl | 32 | $1,465 |
| Hydroxyzine Hcl | 61 | $1,452 |
| Clozapine | 14 | $1,303 |
| Ziprasidone Hcl | 12 | $970 |
| Clonazepam | 175 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $699 | $261,51659 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $995 | $185,74823 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,055 | $88,51613 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,042 | $49,60520 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $12638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Rosenberg
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.